H.C. Wainwright analyst Ed Arce downgraded Ardelyx (ARDX) to Neutral from Buy with a price target of $5.50, down from $11, after the company confirmed that Judge Beryl Howell of the U.S. District Court for Washington, D.C. granted defendants’ motion to dismiss the lawsuit filed by Ardelyx, the American Association of Kidney Patients and the National Minority Quality Forum. The firm now sees a “significant overhang on investor sentiment and the stock” until there is a definitive resolution to the uncertainty around Medicare patient access for Xphozah.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARDX:
- Ardelyx down 21% to $5.30 after judge dismisses lawsuit against CMS
- Ardelyx ‘disappointed’ by court decision granting motion to dismiss
- Ardelyx price target lowered to $10 from $12 at Citi
- Ardelyx price target raised to $13.50 from $12.50 at Ladenburg
- Ardelyx Reports Robust Q3 2024 Revenue Growth
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
